Posts tagged cell membrane
Leerink starts Proteostasis Therapeutics at outperform

Leerink Partners has initiated coverage of Proteostasis Therapeutics (NASDAQ: PTI) with an “outperform” rating and $13 price target in 12 months. The stock closed at $5.56 on Friday.

Proteostasis’ lead candidate, PTI-428, is designed to work as an “amplifier,” which can work additively with Orkambi (corrector/potentiator combination) to increase functioning cystic fibrosis transmembrane conductance regulator (CFTR) on the cell membrane.

Read More